Paper Details

  1. Home
  2. Paper Details

Prevalence of aphthous stomatitis in patients with inflammatory bowel disease after the treatment with monoclonal antibodies: a systematic review and meta-analysis.

Author: Garcillán-IzquierdoM-R, KewalramaniN, Mateos-MorenoM-V, Montero-AlonsoM, Pérez-SayánsM, Salgado-PeralvoA-O

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

This study aims to determine which type of medication, anti-TNFs or vedolizumab (VDZ), is better at reducing mouth sores (aphthous stomatitis or AS) in people with inflammatory bowel disease (IBD). AS is a common complication of IBD, and the study seeks to compare the effectiveness of these medications in managing this symptom.
Paper Details　
Original Abstract of the Article :
Currently, the most frequently employed therapies in the treatment of inflammatory bowel diseases (IBD), i.e., Crohn's Disease (CD), Ulcerative Colitis (UC) or unclassified IBD (IBD-U) are monoclonal anti-TNFs and anti-integrin therapies, such as vedolizumab (VDZ). Forty-seven per cent of these pati...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648636/

データ提供：米国国立医学図書館（NLM）

Monoclonal Antibodies and Aphthous Stomatitis in Inflammatory Bowel Disease: A Meta-Analysis

This research examines the prevalence of aphthous stomatitis (AS), a common extra-intestinal manifestation of inflammatory bowel disease (IBD), in patients treated with monoclonal antibodies. It's like investigating the impact of different treatments on a specific side effect of a particular illness. The study conducted a meta-analysis, combining data from multiple studies to provide a comprehensive overview of the association between monoclonal antibodies and AS. It's like gathering a collection of sand grains to form a larger picture of the desert landscape. The analysis suggests that both anti-TNF and anti-integrin therapies can be associated with AS, highlighting the need for careful monitoring and management of this extra-intestinal manifestation. This study provides valuable information for clinicians managing IBD, offering insights into the potential side effects of different treatment approaches.

Navigating the Side Effects of Treatment

The study highlights the potential association between monoclonal antibodies and AS in IBD patients. It's like understanding the potential consequences of different paths through the desert, some leading to smoother terrain while others present challenges. This research emphasizes the importance of carefully monitoring patients for extra-intestinal manifestations and managing any side effects that may arise.

Understanding the Impact of Different Therapies

The study examines the impact of both anti-TNF and anti-integrin therapies on AS. It's like comparing two different approaches to navigating a desert, each with its own potential benefits and drawbacks. This research provides valuable insights into the potential side effects of different therapies and helps clinicians make informed decisions about the best treatment options for their patients.

Dr. Camel's Conclusion

This meta-analysis sheds light on the prevalence of AS in IBD patients treated with monoclonal antibodies. It's like a roadmap through the intricate world of IBD treatment, highlighting potential challenges and providing guidance for clinicians. This research emphasizes the importance of careful monitoring and management of AS, ensuring the best possible outcome for patients with IBD.

Date :
  1. Date Completed 2022-11-01
  2. Date Revised 2022-11-15
Further Info :

Pubmed ID

36173720

DOI: Digital Object Identifier

PMC9648636

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.